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A new series of novel 1, 4-disubstituted-3-methyl pyrazolo [4,3-e]-pyrido [1,2-a] pyrimidines have been synthesized 
from a common intermediate, in good yields. These compounds have been screened for their antibacterial and antifungal 
activity against different pathogenic strains of bacteria and fungi. The minimum inhibitory concentration (MBC) and 
minimum fungicidal concentration (MFC) have been determined for the test compounds as well as for reference standards. 
Compounds 3d, 3e, 3f, 3h have shown good antibacterial activity whereas compounds 3a, 3b, 3c, 3g have displayed better 
antifungal activity. 
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Michael addition of nucleophiles to electron deficient 
alkenes is one of the most powerful and widely used 
synthetic tools for the formation of carbon-carbon and 
carbon-hetero bonds in organic chemistry1-5. Hetero 
Michael additionsare the most exploited organic 
reactions and are the mainstay of efficient synthetic 
tools for the construction of druggable heterocyclic 
scaffolds and natural products6-8. Construction of 
molecular architecture by two or more bond formation 
in one-step operation via Michael reaction has been 
one of the current interest in synthetic organic 
chemistry9,10. Azole containing compounds exhibit 
both antibacterial and antifungal activities and some 
of them are in clinical practice as antimicrobial 
agents. Because of the extensive use of these azole 
drugs, some microbial strains have developed 
resistance to these drugs. The increasing number of 
azole drug resistant strains has initiated research to 
develop new antimicrobial compounds. Some 
pyrazole derivatives are extensively studied and used 
as antimicrobial agents11-17. Pyrazoles are an 
important class of heterocyclic compound and many 
pyrazole derivatives are reported to have 








antitumor, cytotoxic23, and antiviral24,25 activities. 
Pyrozole derivatives also act as antiangiogenic 
agents26, A3 adenosine receptor antagonists27. The 
heterocyclic fusion of pyrimidine and pyridine rings 
resulted in formation of pyridopyrimidines, the 
structural analogs of biogenic quinazolines and 
pteridines. 
Pyridopyrimidines and related fused heterocycles 
are of interest as potential bioactive molecules. Also, 
due to the presence of pyridopyrimidine moiety in 
some important drugs, interest in the construction of 
such molecules has been aroused. In the last few 
years, an enormous number of papers and reviews 
have been reported dealing with the chemistry and 
application of this class of compounds28-31. Pyrido [1, 
2-a] pyrimidine isomers are found to be biologically
active in a wide range such as antimalarial agents32,
psychotropic agents33,34, anti allergic agents35, the
human leukocyte elastase inhibitor36, anti-ulcer
agent37, CNS stimulants38, urease inhibitor39 and
aggregation of human platelets inhibitors40. The high
therapeutic properties of the compounds incorporating
nitrogen heterocyclic have encouraged the medicinal
chemists to synthesize large number of novel
therapeutic agents.
In light of the above literature and abundance on 
bio-potentials of pyrazolo and pyridopyrimidine 
analogues, we designed the synthesis of titled 
compounds and were confident that these frame work 
would provide the important structural motifs for the 
discovery of new antimicrobial agents. In 




continuation of our research an efficient synthesis of 
biologically active small molecules41, we developed 
an efficient synthesis of 1, 4-disubstituted-3-methyl 
pyrazolo [4, 3-e]-pyrido [1, 2-a] pyrimidine 
derivatives and demonstrated their antimicrobial 
activity. The structure of these compounds was 
established by the IR, 1HNMR spectral data and 
elemental analysis (Scheme I). 
A plausible mechanism for the formation of titled 
1, 4-disubstituted-3-methyl pyrazolo [4, 3-e]-pyrido 
[1, 2-a] pyrimidine is given in (Scheme II). 
The required starting material 1-aroyl/aroyloxy-4-
arylideno-3-methyl-pyrazolin-5-ones was prepared by 
the following known methods42,17. A mixture of 1-
aroyl/aroyloxymethyl-3-methyl-pyrazolin-5-one, 
fused sodium acetate and an araldehyde in glacial 
acetic acid was refluxed for 2-3h. The reaction 
mixture was poured in to cold water, filtered, dried 
and recrystallised from methanol to furnish the 
corresponding pyrazolin derivatives. 
Fungicidal Activity 
National Committee for Clinical Laboratory 
Standards. Reference method for broth dilution 
antifungal susceptibility testing of yeasts: approved 
standard. NCCLS document M27-A. Wayne, Pa: 
National Committee for Clinical Laboratory 
Standards; 1997 
The synthesized pure compounds were screened for 
their antifungal activities adopting standard protocols. 
The antifungal activity, of prepared final pure 
compounds was performed against Pyricularia oryzae 
(ATCC 15024) Pseudoperonospora cubensis (ATCC 
74149), Sphaerotheca fuliginea (ATCC 74387) and 
Phytophthora infestans ( ATCC 96155) using Nystatin. 
Minimum inhibitory concentration (MIC) was 
determined and reported in g/mL as positive and 
DMSO as negative control. Antifungal activity was 
carried out through broth diffusion method43, All fungal 
cultures were routinely maintained on Sabouraud 








The summarized data are presented in Table I, only 
for those compounds which were found active against 
any of these strains of fungi. It is evident from Table I 
that compounds 3a, 3b, 3c and 3g showed antifungal 
activity against used strains of fungi ranging from 9 to 
20 g/mL concentrations. The compound 3gwas the 
only active compounds against P. Cubensis and S. 
fuliginea in 20 and 14 ug/mL concentration 
respectively. Compound3c was found active against 
P. oryzae at 15 g/mL concentration. 
 
Antibacterial Activity 
The newly prepared compounds were screened44 
for their antibacterial activity against Staphylococcus 
aureus ,(ATCC 25923); Escherichia coli (ATCC 64) 
and Klebsiella pneumonia (ATCC 424) using 
ciprofloxacin as positive and DMSO as negative 
Control. Minimum inhibitory concentration (MIC) 
and minimum bactericidal concentration (MBC) were 
determined and the activity was reported in g/mL. 
The nutrient broth, which contained logarithmic 
serially two fold diluted amount of test compounds 
and controls was inoculated with approximately 
5×105 c.f.u/mL of activity dividing bacteria cells. The 
cultures were incubated for 24 h at 37°C and  
the growth was monitored visually and 
spectrophotometrically. The antibacterial results in 
Table II are summarized only for those compounds 
which were found active against any strain of 




Table I — Antifungal activity of compounds3a, 3b, 3c and 3g 
 
Compd 
Fungal species and MIC ( g/mL) 
P. oryzae P. cubensis S. fuliginea P. infestans 
3a 12 9 9 11 
3b 11 11 9 10 
3c 15 n.a. n.a. n.a. 
3g n.a. 20 14 n.a. 
Nystatin 18 20 18 18 
DMSO n.a. n.a. n.a. n.a. 
MIC ( g/mL), minimum inhibitory concentration i.e. the lowest 
concentration of the compounds to inhibit the growth of fungi. 
n.a. - no activity detected. 
 







S. aureus E. coli K. pneumonia 
MIC MBC MIC MBC MIC MBC 
3d 40 100 n.a. n.a. n.a. n.a. 
3e 30 100 n.a. n.a. n.a. n.a. 
3f n.a. n.a. 25 50  n.a. 
3h n.a. n.a. n.a. n.a. 30 50 
Ciprofloxacin 6.5 12.5 6.25 25 6.25 10.50 
DMSO n.a. n.a. n.a. n.a. n.a. n.a. 
MIC ( g/mL), minimum inhibitory concentration i.e. the lowest 
concentration of the compounds to inhibit the growth of bacteria 
completely. 
MBC ( g/mL) minimum bactericidal concentration i.e. the lowest 
concentration of the compound for killing the bacteria completely, 
n.a. – no activity detected. 




3d and 3e showed moderate activity against gram-
positive bacteria S. aureus whereas 3f was active 
against gram-negative E. coli ranging at 25 g/mL 
and compound 3h was found active against  
K. pneumoniae ranging from 30-50 g/mL 
concentration (Table II). 
The antifungal screening data of the tested 
compounds revealed that most of them showed weak 
to moderate activity. Although all of them have polar 
substituents like, Cl, 2,4- Cl2 or -OH in their 
structures. The compound no3g having three - OCH3 
and one methoxypheyl groups showed some 
promising antifungal on P. cubensis. The antibacterial 
activity data reflects that none of the compounds of 
this series possess promising activity except 
compound no 3f which have notable activity on  
E. coli. Thus none of the compounds of this series 
possess antifungal and antibacterial activity 
comparable to commercial compounds tested under 
similar conditions.  
 
Experimental Section 
Melting points were recorded in Richerf- 
Thermover instrument and are uncorrected. The IR 
spectra were recorded on Parkin- Elmer- RXI 
spectrometer in KBr. 1H and 13C NMR spectra were 
recorded on Bruker 300 and BrukerAvance II 400 
spectrometer using tetra methylsilane (TMS) as an 
internal standards and DMSO-d6/CDCl3 as solvent. 
The micro analytical data werecollected on Elemental 
Vario EL III element analyzer. All chemicals used 
were purchased from Merck and Fluka Chemicals. 
The homogeneity of compounds was checked by thin 
layer chromatography (TLC) on glass plates coated 
with silica gel G254 (Merck, Mumbai, India) using 
chloroform-methanol (3:1) mixture as mobile phase. 
 
General procedure for synthesis of l-4-
disubstituted- 3-methyl pyrazolo[4, 3-e]-pyrido[1, 
2-a]pyrimidines 
A mixture of 1-aroyl/aroyloxymethyl-4-arylideno-
3-methyl pyrazolin-5-one (0.01 mol), 2-amino 
pyrimidine (0.01mol) in glacial acetic acid (10 mL) 
was refluxed for 8h. The resulting solution was cooled 
and poured in to water. The solid product obtained 
was filtered and washed with water, dried and purified 
by recrystallization from ethanol to get crystalline 
solid products 3a-h. 
3a: Colourless solid Yield 65% m.p. 205 C; IR: 
3050(C-H arom), 1710 (C=O), 1275 (C=C of benzene 
ring)cm-1; 1H NMR (DMSO-d6): δ7.33-8.59 (m, 8 
CH arom. proton), 6.12-6.20 (m 4H pyridine ring 
proton), 2.75 (s, J =4Hz ,3H, CH3);
13C NMR (δ ppm) 
: δ 15.2, 111.3,113.1,120.5,124.9, 129.6, 130.7, 134.5, 
138.5, 141.9, 143.3, 146.2, 148.3, 151.6, 155.2, 156.0, 
158.1, 160.8, 163.0, 163.7, 168. 
Molecular formula C23H16N4OCl2, (m/z) (M
+): 
434.880 
3b: Colourless solid Yield 69% m.p. 201 C; IR: 
3060 (C-H arom), 1725 (C=O), 1225 (C=C of 
benzene ring)cm-1; 1H NMR (DMSO-d6): δ 7.10-7.69 
(m, 8 CH arom. proton),6.36-6.41 (m 4H pyridine 
ring proton),3.50 (s, 3H OCH3 proton), 2.75 (s, J 
=4Hz ,3H, CH3);
13C NMR (δ ppm) : δ 11.6, 55.9, 
92.0,110.3,113.8,120.2,124.0, 129.2, 131.7, 133.5, 
137.5, 141.5, 143.8, 145.2, 148.6, 150.6, 154.2, 158.0, 
158.9, 160.8, 163.2, 164.7, 168.C24H18N4O2Cl2, (m/z) 
(M+): 465.332 
3c: Colourless solid Yield 65% m.p. 216 C; IR: 
3045 (C-H arom), 1715 (C=O), 1210 (C=C of 
benzenering)cm-1; 1H NMR (DMSO-d6): δ 7.00-7.94 
(m, 8 CH arom. proton),6.26-6.38 (m 4H pyridine 
ring proton), 5.0 (s 1H hydroxyl proton), 3.50 (s, 3H 
OCH3 proton), 2.75 (s, J =4Hz ,3H, CH3);
13C NMR 
(δ ppm) : δ 11.6, 55.9, 92.0,114.3,115.8,121.2,124.9, 
126.4, 129.2, 131.7, 133.6, 137.7, 141.1, 143.3, 145.5, 
147.6, 150.8, 154.4, 158.4, 158.9, 160.8, 163.2, 164.7, 
168.0 C24H20N4O3, (m/z) (M
+): 412.34 
3d: Colourless solid Yield 53% m.p. 192 C; IR: 
3035 (C-H arom), 1705 (C=O), 1205 (C=C of 
benzene ring)cm-1; 1H NMR (DMSO-d6): δ 7.35-8.34 
(m, 7 CH arom. proton),6.0-6.17 (m 4H pyridine ring 
proton), 3.72 (s, 6H OCH3 proton), 2.75 (s, J =4Hz 
,3H, CH3);
13C NMR (δ ppm) : δ 11.6, 56.9, 56.9, 
92.2,114.4,115.5,121.1,124.4, 126.6, 129.9, 131.1, 
133.3, 137.7, 141.9, 143.6, 145.7, 147.3, 151.8, 154.6, 
158.0, 158.9, 160.8, 163.2, 164.7, 168.2 C25H21N5O5, 
(m/z) (M+): 470.900 
3e: Colourless solid Yield 70% m.p. 225 C; IR: 
3020 (C-H arom), 1710 (C=O), 1210 (C=C of 
benzene ring)cm-1; 1H NMR (DMSO-d6): δ 7.30-8.38 
(m, 8 CH arom. proton),6.10-6.21 (m 4H pyridine 
ring proton), 2.75 (s, J =4Hz ,3H, CH3);
13C NMR (δ 
ppm) : δ 11.6, 92.2,112.0,115.3,121.0,124.2, 126.0, 
129.2, 131.4, 133.5, 137.8, 141.6, 143.7, 145.8, 147.9, 
151.4, 154.6, 158.2, 159.0, 160.8, 163.2, 164.5, 168.1 
C23H17N3O5Cl, (m/z) (M
+): 445.52 
3f: Colourless solid Yield 69% m.p. 190 C; IR: 
3025 (C-H arom), 1690 (C=O), 1220 (C=C of 
benzene ring)cm-1; 1H NMR (DMSO-d6): δ 6.80-7.58 




(m, 9 CH arom. proton),6.15-6.26 (m 4H pyridine 
ring proton), 4.79 (s 2H OCH2 proton), 2.75 (s, J 
=4Hz ,3H, CH3);
13C NMR (δ ppm) : δ 11.6, 55.9, 
74.6, 83.3, 92.2, 109.5,112.0,115.3, 120. 8, 127.0, 
128.5, 129.2, 131.4, 133.5, 135.4, 136.6, 137.8, 141.6, 
143.7, 145.8, 147.9, 151.4, 154.6, 158.2, C25H22N4O3, 
(m/z) (M+): 425.645 
3g: Colourless solid Yield 68% m.p. 165 C; IR: 
3025 (C-H arom), 1690 (C=O), 1220 (C=C of 
benzene ring)cm-1; 1H NMR (DMSO-d6): δ 6.80-7.58 
(m, 9 CH arom. proton),6.18-6.25 (m 4H pyridine 
ring proton), 4.79 (s 2H OCH2 proton), 2.75  
(s, J =4Hz ,3H, CH3);
13C NMR (δ ppm) : δ 11.6, 55.9, 
74.6, 83.3, 92.2, 109.5,112.0,115.3, 120. 8, 127.0, 
128.5, 129.2, 131.4, 133.5, 135.4, 136.6, 137.8, 141.6, 
143.7, 145.8, 147.9, 151.4, 154.6, 158.2, C27H26N4O4, 
(m/z) (M+): 470.22 
3h: Colourless solid Yield 60% m.p. 208C; IR: 
3025 (C-H arom), 1695 (C=O), 1255 (C=C of 
benzene ring)cm-1; 1H NMR (DMSO-d6): δ 6.69-7.19 
(m, 8 CH arom. proton), 6.15-6.20 (m 4H pyridine 
ring proton), 4.79 (s 2H OCH2 proton), 3.73 (s, 6H 
OCH3 proton), 2.75 (s, J =4Hz ,3H, CH3);
13C NMR (δ 
ppm) : δ 11.6, 56.2, 56.2, 74.6, 83.3, 92.2, 
109.4,114.0,115.2, 122.8, 127.0,129.2, 132.4, 134.5, 
136.4, 137.8, 138.9, 141.6, 143.7, 145.8, 146.2 147.9, 





In the present investigation, a series of new 
heterocycles have been synthesized and screened for 
their antifungal and antibacterial activity. The activity 
results reveal that the synthesized compounds possess 
moderate to good activity profiles. The insights 
gained in this study will be useful for development of 
newer anti-infective agents. 
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